- Poster presentation
- Open Access
Monitoring of treatment with low molecular weight heparins using viscoelastic devices
Critical Care volume 18, Article number: P95 (2014)
Few studies have investigated the use of viscoelastic devices for monitoring of treatment with LMWHs and to our knowledge there are no studies comparing different LMWHs or different visocoelastic methods.
Enoxaparin (Klexane) and tinzaparin (Innohep) were added to 2 ml citrated blood from 10 intensive care patients to obtain plasma concentrations of 0, 0.5, 1.0 and 1.5 IU/ml enoxaparin and tinzaparin, respectively. The study was approved by the local ethics committee and with written consent (relatives). Clot formation and clot retraction was studied using ROTEM and ReoRox.
ROTEM analysis showed prolonged clot formation (CT) with increasing concentrations of enoxaparin and tinzaparin (more so). ReoRox analysis showed that the initiation of clot formation (COT1) increased with increasing doses of enoxaparin and tinzaparin (more so), as did the progression of clot formation (COT2 - COT1), thus resulting in a prolongation until complete clot formation (COT2). See Table 1.
Clot initiation was prolonged with both drugs and detected by both ROTEM and ReoRox. Clot formation was more decreased with tinzaparin than enozaparin and only detected by ReoRox.
About this article
Cite this article
Schött, U., Larsson, A., Thomas, O. et al. Monitoring of treatment with low molecular weight heparins using viscoelastic devices. Crit Care 18, P95 (2014). https://doi.org/10.1186/cc13285
- Molecular Weight
- Plasma Concentration
- Care Patient